Mystical Experiences Predict OCD Improvement with Psilocybin

Psiconáutica Editorial Team · September 30, 2026

Individuals who experienced sensations of unity, sacredness, and transcendence during a psilocybin session showed fewer symptoms of obsessive-compulsive disorder (OCD) in the following weeks. This is according to an analysis by the Yale team published on September 8, 2026, in Frontiers in Psychiatry, using data from people whose OCD had not responded to other treatments.

An analysis of an existing trial

The authors did not conduct a new patient trial. Instead, they reused data from a phase 2, randomized, double-blind, niacin-placebo-controlled trial, followed by an open-label phase in which the placebo group could receive psilocybin after the first week. Participants were adults aged 18 to 65 with treatment-resistant OCD (at least two failed adequate treatments) and a baseline score of 19 or higher on the Y-BOCS scale. The dose was a single administration of 0.25 mg/kg.

Of the original group of 28 people, 27 were included in the analysis because one participant lacked complete data. The day after their session, each participant completed two questionnaires: the MEQ-30, which measures mystical-type experiences, and the CEQ, which captures challenging experiences. The results were then compared with OCD severity measured by the Y-BOCS at one and twelve weeks.

What the numbers show

A higher total score on the MEQ-30 was associated with fewer symptoms at both one week (r = -0.535) and twelve weeks (r = -0.481), after adjusting for baseline severity and treatment group. The “mystical” subscale, which captures unity, sacredness, and transcendence, was the most consistent: r = -0.606 at one week and r = -0.501 at twelve weeks. The space-time subscale was only associated with fewer symptoms at twelve weeks. The positive mood and ineffability subscales did not reach significance after correcting for multiple comparisons.

Challenging experiences, by contrast, showed no significant relationship with subsequent severity: the correlation was practically zero at one week (r = -0.007) and -0.155 at twelve weeks. With such a small sample, the authors themselves urge caution: the study may have lacked the power to detect smaller effects, and the questionnaire does not distinguish between unresolved distress and a difficult experience that was later integrated.

What this implies

The results align with previous observations in depression, anxiety, and addiction, and the authors note that this had not yet been examined in OCD. The authors suggest paying attention to the quality of the experience when planning dosage, environment, preparation, and integration.

The limitations are clear. There are only 27 people, the analysis is exploratory and has low statistical power, the follow-up is cut off at twelve weeks, and the sample is homogeneous in terms of race and ethnicity. A correlation does not prove that the experience causes the improvement: it could be that those who respond best to the drug also have more intense sessions. The authors themselves mention expectations and selection bias as potential distortions. The work was funded by the Yale Center for Clinical Investigation, the Heffter Foundation, and the Turnbull Family Foundation, among others, and the Usona Institute provided the psilocybin. For general context on the substance, you can consult our Psychedelics Guide on psilocybin and magic mushrooms.

Source

• Shnayder S, Agin-Liebes G, Hubert TJ, Ching THW, Hokanson J, Pittenger C, Kelmendi B, Adams T. Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD. Frontiers in Psychiatry, September 8, 2026.

Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.